Abstracts tagged "immunoregulation"

Abstract Number: 4 • 2019 ACR/ARP Annual Meeting
AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers¹, Aditi Kuppe ¹, Cindy Strehl ¹, Marieluise Kirchner ², Frank Buttgereit ³ and Timo Gaber ¹, ¹Charite University Hospital Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine, BIH Core Facility Proteomics, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Adenosine and its nucleotides represent crucial immunomodulators in the extracellular environment. ATP and ADP are released from stressed cells in states of inflammation, whereas…
Abstract Number: 1000 • 2018 ACR/ARHP Annual Meeting
Surface Adenosine Monophosphate Deaminase 2 As a Novel Regulator Modifying Ectonucleotidase-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers^1,2, Aditi Kuppe^1,2, Alexandra Damerau^3,4, Yuling Chen^1,2, Cindy Strehl^3,5, Marieluise Kirchner⁶, Frank Buttgereit¹ and Timo Gaber^3,5, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²German Rheumatism Research Centre Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁵Deutsches Rheuma Forschungszentrum (DRFZ) Berlin, Berlin, Germany, ⁶BIH Core Facility Proteomics, Max Delbrück Centre for Molecular Medicine, Berlin, Germany
Background/Purpose: Extracellular ATP and adenosine are potent immunomodulatory molecules that accumulate in states of inflammation. ATP/ADP are released from damaged or stressed cells and sequentially…
Abstract Number: 2544 • 2018 ACR/ARHP Annual Meeting
Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy
Xiaoxia Jia¹, Fang Li², Jing Luo³, Chong Gao⁴ and Xiao-Feng Li¹, ¹Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ³the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Recent studies have showed that quantitative and/or functional abnormalities of the regulatory T cells (Tregs) may play a vital role in the development of…
Abstract Number: 1091 • 2016 ACR/ARHP Annual Meeting
Synergistic Immunoregulatory Effects of IL-10 and TGF-β on Humoral Immunity
Toshihiko Komai¹, Tomohisa Okamura^1,2, Mariko Inoue¹, Yukiko Iwasaki¹, Kaoru Morita¹, Kazuhiko Yamamoto¹ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Max Planck-The University of Tokyo Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan
Background/Purpose: We have previously identified CD4+CD25-Foxp3- regulatory T cells (Treg) that characteristically express lymphocyte-activation gene 3 (LAG3) produce IL-10. Recently we reported that these Treg…
Abstract Number: 1739 • 2014 ACR/ARHP Annual Meeting
Immunomodulatory Properties of CD271+ and CD271- Synovial Mesenchymal Cells
Alicia Usategui¹, Manuel J. Del Rey¹, Regina Faré¹, Gabriel Criado², Vanessa Miranda¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose Mesenchymal stem cells (MSC) have been isolated from synovium and represent a fraction of synovial fibroblast (SF) cultures. CD271+ is considered a MSC surface…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].